Tech Company Financing Transactions

Memento Medicines Funding Round

Memento Medicines closed a $93 million Series A financing round on 6/19/2026. Investors included Avego Healthcare Capital, Forbion Capital Partners and RA Capital Management.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

200 Berkeley Street, 18th Floor
Boston, MA 02116
USA

Phone

Undisclosed

Website

Email Address

Not Recorded

Overview

Memento Medicines is a biotech company advancing novel antibody therapies for ophthalmology. Founded in 2026 as the fifth subsidiary of Sera Medicines, a biologics-focused antibody accelerator formed in collaboration with RA Capital, the Company is committed to developing new therapies for patients living with retinal diseases. Memento's lead program, MMT-205, is a potential best-in-class bispecific antibody that activates Tie2 and inhibits VEGF, in development for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Naveen Daryani

        

Browse more venture capital transactions:

Prev: 6/19/2026: Andera venture capital transaction
Next: 6/21/2026: Franklin venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary